Online inquiry

IVTScrip™ mRNA-Anti-PCSK9, aPCSK927(Cap 1, 5-Methyl-CTP, 30 nt-poly(A))   (CAT#: GTTS-WQ14146MR)

This product GTTS-WQ14146MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 1 & 5-Methyl-CTP. It ecodes the monoclonal antibody that targets PCSK9 gene. The antibody can be applied in Atherosclerosis&Acute coronary syndrome (ACS) research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP
5' Cap Cap 1
Species Homo sapiens
RefSeq NM_174936.4
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 255738
UniProt ID Q8NBP7
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-PCSK9, aPCSK927(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) (GTTS-WQ14146MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ2435MR IVTScrip™ mRNA-Anti-TSLP, AMG 157(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA AMG 157
GTTS-WQ2393MR IVTScrip™ mRNA-Anti-CD3E&EPCAM, AMG 110(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA AMG 110
GTTS-WQ2532MR IVTScrip™ mRNA-Anti-GCGR, AMG 477(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA AMG 477
GTTS-WQ886MR IVTScrip™ mRNA-Anti-PDCD1, ABBV-181(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA ABBV-181
GTTS-WQ4831MR IVTScrip™ mRNA-Anti-CD4, BT-061(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA BT-061
GTTS-WQ4028MR IVTScrip™ mRNA-Anti-IL23A, BI 655066(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA BI 655066
GTTS-WQ7555MR IVTScrip™ mRNA-Anti-GPC3, GC33(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA GC33
GTTS-WQ1842MR IVTScrip™ mRNA-Anti-IL17A, AG1-25(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA AG1-25
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW